BRONCHOGEN 20 MG

Bronchogen 20 mg – Peptide Hubs

Bronchogen is a specialized research peptide formulated to support pulmonary tissue regeneration, bronchial healing, and airway inflammation modulation. The 20 mg lyophilized vial from Peptide Hubs provides researchers a high-purity tool for studying respiratory distress, bronchial inflammation, and post-infection lung tissue recovery.

What Is Bronchogen?

Bronchogen is designed to mimic endogenous peptides that regulate epithelial cell repair and anti-inflammatory activity in lung tissues. It is commonly studied in preclinical models involving chronic obstructive pulmonary disease (COPD), bronchitis, asthma, and respiratory damage following viral infections or environmental toxins.

Mechanism of Action

While the exact mechanism may vary depending on research protocol, Bronchogen is believed to support regeneration of epithelial tissue in the bronchial tree and alveolar lining. It may reduce inflammatory cytokine expression, support ciliary function, and promote localized healing in lung microenvironments. Studies suggest potential cross-over with pathways involving peptides like LL-37 or thymosin beta-4.

To explore more about lung-repair peptides, visit this NIH review of pulmonary peptide therapeutics.

Research Applications

Bronchogen 20 mg is used in experimental protocols investigating:

• Bronchial epithelial regeneration
• Recovery from acute respiratory distress syndrome (ARDS)
• Post-viral lung inflammation
• Asthma and COPD models

Researchers have also studied Bronchogen alongside peptides like BPC-157 and Semax for comprehensive recovery in pulmonary and systemic inflammation models.

Suggested Experimental Use

• Dose: 10–20 mg per day (split or single administration)
• Administration: Subcutaneous or intranasal (depending on delivery study)
• Cycle: 7–21 days in respiratory repair protocols

Stacking Options

Bronchogen is often stacked in research with the following compounds for synergistic outcomes:

• GHK-CU – lung and skin regeneration
• ARA-290 – for inflammation and nerve modulation
• AOD 9604 – metabolic support in post-repair models

Safety Profile

Bronchogen does not impact hormonal levels, is non-toxic to the liver, and does not promote androgenic or estrogenic activity. Side effects in research models are rare and typically limited to mild site irritation or transient fatigue.

Legal Disclaimer

Bronchogen is not approved by the FDA for medical use and is sold exclusively for laboratory and research purposes. It must not be used in humans or animals outside controlled environments. For regulatory updates, visit the ClinicalTrials.gov database.

Frequently Asked Questions